CTMX Share Price Performance
US$0
-2.31 (-100.00%)
Price US$0
Fair ValueUS$12.44
Share Pricen/a
New Narrative • Aug 08
CytomX Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 43 Fair Values set on narratives written by author
CTMX Community Narratives
AN
Fair Value
·Fair Value US$12.44 72.3% undervalued intrinsic discount
CTMX: Clinical Momentum Will Drive Shares Higher Despite Recent Safety Concerns
1users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value
·Fair Value US$16 78.4% undervalued intrinsic discount
KEYTRUDA And CX-2051 Trials Will Expand Immuno-Oncology Reach Despite Risks
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value US$6.38 45.9% undervalued intrinsic discount
Late-Stage Oncology Setbacks Will Test This ADC Pipeline Before Longer-Term Promise Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Late-Stage Oncology Setbacks Will Test This ADC Pipeline Before Longer-Term Promise Emerges
CytomX Therapeutics is leaning hard on a lead cancer drug that aims to hit tumors while sparing the rest of the body, but the next clinical readouts could expose safety and effectiveness limits that slow its path forward. The company also has earlier programs and big partners in the background, yet the long timelines and crowded cancer space may mean more waiting—and possible fundraising—before the longer-term promise shows up.Read more
AN
US$6.38
45.9% undervalued intrinsic discount
Fair Value
Profit Margin
18.48%
Future PE
477.29x
Price in 2029
US$4.41
KEYTRUDA And CX-2051 Trials Will Expand Immuno-Oncology Reach Despite Risks
CytomX is betting that its tumor-targeted drug platform can make existing cancer medicines work in more patients, with early signs that its lead programs could reach beyond the groups most people expect. The big question is whether the next trial results and partner support show the approach is safe and effective enough to turn a research-heavy story into a real business.Read more
AN
US$16
78.4% undervalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
283.17x
Price in 2029
US$10.95
CTMX: Clinical Momentum Will Drive Shares Higher Despite Recent Safety Concerns
CytomX is betting that its tumor-targeting drug approach can deliver strong cancer treatment results while avoiding the side effects that often limit older therapies. Early patient data looks promising, but safety concerns, uncertain approvals, and reliance on partners mean the path ahead could still get rocky.Read more
AN
US$12.44
72.3% undervalued intrinsic discount
Fair Value
Profit Margin
19.04%
Future PE
495.57x
Price in 2029
US$8.5
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Late-Stage Oncology Setbacks Will Test This ADC Pipeline Before Longer-Term Promise Emerges
Fair Value: US$6.38 45.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CTMX: De Risked Epithelial Program And Pullback Will Support Future Repricing
Fair Value: US$16 78.4% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CTMX: Late-Line Colorectal Cancer Data Will Drive Upward Repricing Expectations
Fair Value: US$12.44 72.3% undervalued intrinsic discount
18 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
CytomX Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.38
- 100.00%
- -451.59%
- 0%
About CTMX
- Founded
- 2008
- Employees
- 69
- CEO
- WebsiteView website
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
